Our top pick for
BioLineRx Ltd is a biotechnology business based in the US. BioLineRx shares (BLRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioLineRx employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$1.40 - $4.23|
|50-day moving average||$2.89|
|200-day moving average||$2.67|
|Wall St. target price||$11.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.84|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||$0|
|Return on assets TTM||-28.42%|
|Return on equity TTM||-108.36%|
|Market capitalisation||$128.4 million|
TTM: trailing 12 months
There are currently 401,164 BioLineRx shares held short by investors – that's known as BioLineRx's "short interest". This figure is 3% down from 413,394 last month.
There are a few different ways that this level of interest in shorting BioLineRx shares can be evaluated.
BioLineRx's "short interest ratio" (SIR) is the quantity of BioLineRx shares currently shorted divided by the average quantity of BioLineRx shares traded daily (recently around 417879.16666667). BioLineRx's SIR currently stands at 0.96. In other words for every 100,000 BioLineRx shares traded daily on the market, roughly 960 shares are currently held short.
However BioLineRx's short interest can also be evaluated against the total number of BioLineRx shares, or, against the total number of tradable BioLineRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioLineRx's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioLineRx shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioLineRx shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioLineRx.
Find out more about how you can short BioLineRx stock.
We're not expecting BioLineRx to pay a dividend over the next 12 months.
BioLineRx's shares were split on a 1:15 basis on 14 July 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.
Over the last 12 months, BioLineRx's shares have ranged in value from as little as $1.4 up to $4.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 1.608. This would suggest that BioLineRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioLineRx Ltd. , a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.